Effectiveness of palosuran in bleomycin-induced experimental scleroderma

Inflammation

Volumn 36, Issue 1, 2013, Pages 75-79

  Demir, Tuncer ^a   Turkbeyler, Ibrahim ^a   Kaplan, Davut Sinan ^a   Pehlivan, Yavuz ^a   Orkmez, Mustafa ^a   Tutar, Ediz ^a   Taysi, Seyithan ^a   Kisacik, Bunyamin ^a   Onat, Ahmet Mesut ^a   Bagcı, Cahit ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

endothelin 1; palosuran; systemic sclerosis; urotensin II

Indexed keywords

BLEOMYCIN; ENDOTHELIN 1; PALOSURAN; TRANSFORMING GROWTH FACTOR BETA1; UROTENSIN II; UROTENSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; MALE; MOUSE; NONHUMAN; SCLERODERMA; SKINFOLD THICKNESS; TREATMENT OUTCOME;

ANIMALIA; MUS;

EID: 84872916720     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9521-y     Document Type: Article

References (28)

1. D'Angelo, W.A., J.F. Fries, A.T. Masi, L.E. Shulman, et al. 1969. Pathologic observations in systemic sclerosis (scleroderma): A study of fifty-eight autopsy cases and fifty-eight matched controls. American Journal of Medicine 46: 428-440.
2. Jimenez, S.A., and E. Hitraya. 1996. Pathogenesis of scleroderma: collagen. Rheumatic Diseases Clinics of North America 22: 647-674.
3. Varga, J., and D. Abraham. 2007. Systemic sclerosis: A prototypic multisystem fibrotic disorder. The Journal of Clinical Investigation 117: 557-567. (Pubitemid 46348510)
4. Horstmeyer, A., C. Licht, G. Scherr, et al. 2005. Signaling and regulation of collagen I synthesis by ET-1 and TGF-beta1. FEBS Journal 272: 6297-6309. (Pubitemid 41815618)
5. Uitto, J., and D. Kouba. 2000. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. Journal of Dermatological Science 24: 60-69. (Pubitemid 32008463)
6. Leask, A., C.P. Denton, and D.J. Abraham. 2004. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. The Journal of Investigative Dermatology 122: 1-6. (Pubitemid 38114631)
7. Shi-Wen, X., Y. Chen, C.P. Denton, et al. 2004. Endothelin-1 promotes myofibroblast induction through the ETA receptorviaarac/phosphoinositide 3-kinase/Akt dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Molecular Biology of the Cell 15: 2707-2719. (Pubitemid 38691860)
8. Shi-Wen, X., E.A. Renzoni, L. Kennedy, et al. 2007. Endogenous endothelin-1 signaling contributes to type I collagenand CCN2 overexpression in fibrotic fibroblasts. Matrix Biology 26: 625-632. (Pubitemid 350186096)
9. Yamane, K., H. Kashiwagi, N. Suzuki, et al. 1991. Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis and Rheumatism 34: 243-244.
10. Yamane, K., T. Miyauchi, N. Suzuki, et al. 1992. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. Journal of Rheumatology 19: 1566-1571.
11. Coulouarn, Y., I. Lihrmann, S. Jegou, et al. 1998. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proceedings of the National Academy of Sciences of the United States of America 95: 15803-15808. (Pubitemid 29018781)
12. Wang, H., J.L. Mehta, K. Chen, et al. 2004. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. Journal of Cardiovascular Pharmacology 44: 577-581. (Pubitemid 39441698)
13. Zhang, Y.G.G., Y.G. Li, B.G. LiI, et al. 2007. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacologica Sinica 28: 36-43.
14. Kemp, W., A. Kompa, A. Phrommintikul, et al. 2009. Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats. American Journal of Physiology - Gastrointestinal and Liver Physiology 297: 762-767.
15. Tian, L., C. Li, J. Qi, et al. 2008. Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-β 1 mediated renal fibrosis and dysfunction. American Journal of Physiology, Endocrinology and Metabolism 295: 1234-1242.
16. Dai, H.Y., W.Q. Kang, X. Wang, et al. 2007. The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regulatory Peptides 140: 88-93.
17. Tran, L., A.R. Kompa, W. Kemp, et al. 2010. Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. American Journal of Physiology - Heart and Circulatory Physiology 298: 608-613.
18. Pehlivan, Y., A.M. Onat, G. Comez, et al. 2011. Urotensin-II in systemic sclerosis: A new peptide in pathogenesis. Clinical Rheumatology 30: 837-842.
19. Yamamoto, T., S. Takagawa, I. Katayama, et al. 1999. Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. The Journal of Investigative Dermatology 112: 456-462. (Pubitemid 29171935)
20. Clozel, M., P. Hess, C. Qiu, et al. 2006. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. Journal of Pharmacology and Experimental Therapeutics 316: 1115-1121. (Pubitemid 43345285)
21. Cosenzi, A. 2008. Non peptidic urotensin II antagonists: perspectives for a new class of drugs. Cardiovascular & Hematological Agents in Medicinal Chemistry 6: 80-91. (Pubitemid 351935015)
22. Kompa, A.R., W.G. Thomas, F. See, et al. 2004. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 25: 1783-1788. (Pubitemid 39346221)
23. Sidharta, P.N., P.L. van Giersbergen, and J. Dingemanse. 2009. Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects. Journal of Clinical Pharmacology 49: 1168-1175.
24. Bousette, N., J. Pottinger, W. Ramli, et al. 2006. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27: 2919-2926. (Pubitemid 44584417)
25. Simpson, C.M., J.J. Smolich, L.S. Shekerdemian, et al. 2010. Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome. Pediatric Research 67: 150-157.
26. Trebicka, J., L. Leifeld, M. Hennenberg, et al. 2008. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 47: 1264-1276. (Pubitemid 351547913)
27. Sidharta, P.N., F.D. Wagner, H. Bohnemeier, et al. 2006. Pharmacodynamics and pharmacokinetics of the urotensin-II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clinical Pharmacology and Therapeutics 80: 246-256. (Pubitemid 44313907)
28. Shimokawa, H. 2002. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. Journal of Cardiovascular Pharmacology 39: 319-327. (Pubitemid 34175055)